Poland· PL-100518059
Deqsiga
A humane immunglobuline, unspezifisch, intravaskulär product containing immunoglobulinum humanum normale, registered in Poland by Takeda Manufacturing Austria AG. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Humane immunglobuline, unspezifisch, intravaskulär is registered in 11 of 19 countries.
Countries holding a registration under ATC J06BA02 (humane immunglobuline, unspezifisch, intravaskulär), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Humane immunglobuline, unspezifisch, intravaskulär · ATC J06BA02
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Immunoglobulinum humanum normale
- Manufacturer
- Takeda Manufacturing Austria AG
- Country
- Poland (PL)
- ATC code
- J06BA02
- ATC class
- Humane Immunglobuline, unspezifisch, intravaskulär
- Defined daily dose
- 1.6 g, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
48 interactions on record for humane immunglobuline, unspezifisch, intravaskulär.
Graded by severity as the source publishes them — 44 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Humane immunglobuline, unspezifisch, intravaskulär · interactions on record
48 records
- 44 severe
- 4 minor
Most severe, free to view
- NeomycinA07AA01severe
- StreptomycinA07AA04severe
- Polymyxin BA07AA05severe
- Amphotericin BA07AA07severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under J06BA02
Humane immunglobuline, unspezifisch, intravaskulär, as other registers publish it.
- FinlandDeqsigaTakeda Manufacturing Austria AG
- IcelandDeqsigaTakeda Manufacturing Austria AG
- CzechiaDEQSIGATakeda Manufacturing Austria AG, Vídeň
- CzechiaDEQSIGATakeda Manufacturing Austria AG, Vídeň
- DenmarkDEQSIGATakeda Manufacturing Austria AG
- BelgiumDeqsiga 100 mg/mlTakeda Manufacturing Austria
- BelgiumDeqsiga 100 mg/mlTakeda Manufacturing Austria
- NetherlandsDeqsiga 100 mg/ml oplossing voor infusieTakeda Manufacturing Austria AG
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5ae7099e-08c9-443f-8500-a14fbe782d08 GET /v1/drugs/5ae7099e-08c9-443f-8500-a14fbe782d08?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do infuzji",
"source": "urpl",
"strength": "100 mg/ml",
"packaging": "Rp ¦ EU/1/25/1919/001 ¦ 162071\n1 fiol. 50 ml\nRp ¦ EU/1/25/1919/002 ¦ 162072\n1 fiol. 100 ml",
"substance": "Immunoglobulinum humanum normale 100 mg/ml",
"common_name": "Immunoglobulinum humanum normale",
"pl_product_id": "100518059",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about humane immunglobuline, unspezifisch, intravaskulär.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.